Christian Pangratz

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ.

Dance Biopharm Holdings, Inc. engages in providing health care services. The company was founded by John Stuart Patton in 2010 and is headquartered in San Francisco, CA.

LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies.

IDEA AG develops pain therapeutics and biopharmaceutical drugs. The firm develops and commercializes non-invasive therapeutic drugs and the targeted pain therapeutics for arthritic and osteoporosis-related inflammation, chronic pain and diseases. Its technology platform is based on proprietary carriers applied on skin and engineered to diminish side effects and increase drug potency. The company founded by Gregor Cevc in 1993 and is headquartered in Munich, Germany.

TopoTarget UK Ltd. engages in the discovery and development of drugs and therapies to treat cancer. It develops anti-cancer drugs for molecular mechanisms associated with the cell cycle, chromatin control and DNA damage. The company was founded in 2002 and is headquartered in Oxford, the United Kingdom.

University Hospital Antwerp provides clinical, patient care, academic training and scientific research services. The company was is headquartered in Belgium.

ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium.

OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany.

Ventaleon GmbH is a biotechnology company, which engages in the development of inhaled treatments against viral infections. Its products include LASAG (D,L-lysine acetylsalicylate • glycine), a lysin-salt formulation of well known acetyl salicylic acid. The company was founded by Gerhard Scheuch in 2012 and is headquartered in Gauting, Germany.

Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA.

miDIAGNOSTICS NV develops a computer chip powered portable medical laboratory. The company is headquartered in Leuven, Belgium.

Drug Discovery & Development Solutions Ltd. engages in the provision of financial services. The company is headquartered in Singapore.

Kira Biotech Pty Ltd. operates as biotechnology company which develops novel immunomodulatory compounds for the treatment of immune system disorders. The company was founded by Georgina Clark is headquartered in Brisbane, Australia.

Symeres provides molecule contract research, discovery, development and manufacturing services. The firm offers discovery chemistry, medicinal chemistry, early process research and GMP production services. The company is headquartered in Groningen, the Netherlands.

QrumPharma, Inc. is engaged in developing drug products. It develops inhalation treatments for severe chronic and recurrent pulmonary infections, including Nontuberculous Mycobacterial (NTM) lung disease. The company was founded by Thomas Hofmann and is headquartered in Doylestown, PA.

Curexsys GmbH is a German company founded by molecular biologist Jens Gruber and biochemist Dr. Herbert Stadler. The company is based in Goettingen, Germany. The company aims to become a leading supplier for clinical grade exosomes in regenerative medicine and anti-aging therapies. Exosomes are extracellular, nanoscale vesicles that transfer information to neighboring cells and distant tissues. Curexsys is currently pursuing the development of several programs in three indications, focusing on the generation of clearly defined, characterized, and purified extracellular vesicles/exosomes from their proprietary iMSC lines derived from Evotec's iPSC platform.

Part of Rhythm Pharmaceuticals, Inc., Xinvento BV is a Dutch biotech company that develops therapies for congenital hyperinsulinism. The company is based in Amsterdam, Netherlands. The company was founded in 2021 by Claudine van der Sande, Sarah Hafith-de Boer, Piet Wigerinck. Claudine van der Sande has been the CEO since 2021. Xinvento was acquired by Rhythm Pharmaceuticals Netherlands BV on February 27, 2023 for $222.43 million.

Founded in 2012, Atrin Pharmaceuticals, Inc. is a DNA Damage Response development company that focuses on a pipeline of products resulting from a series of novel conformationally restricted macrocyclic molecules. Part of Aprea Therapeutics, Inc., the company is based in Doylestown, PA. Atrin Pharmaceuticals was acquired by Aprea Therapeutics, Inc. on May 16, 2022 for $1.33 million. The company's products have the highest known potency for inhibiting ATR and exhibit ATR selectivity with potential broad therapeutic profile.